GlaxoSmithKline Plc (GSK)

39.46
0.12 0.30
NYSE : Health Technology
Prev Close 39.34
Open 39.27
Day Low/High 39.27 / 39.68
52 Wk Low/High 36.41 / 42.36
Volume 1.92M
Avg Volume 2.44M
Exchange NYSE
Shares Outstanding 2.49B
Market Cap 98.89B
EPS 2.00
P/E Ratio 22.61
Div & Yield 2.05 (5.21%)
J&J - More Exciting Than Merck

J&J - More Exciting Than Merck

Johnson & Johnson replaces Merck in AAP given better pipeline and stock upside potential, says AAP Co-Portfolio Manager, Stephanie Link.

Futures Point to Higher Open

Futures Point to Higher Open

U.S. stock futures are pointing to a higher open as Obama presses case for military action in Syria.

GlaxoSmithKline upgraded at JP Morgan

Keep Calm and Carry EWU

The UK is the next geographic hotspot. Play it with this ETF.

Glaxo Bribery Claims May be True

Glaxo Bribery Claims May be True

GlaxoSmithKline revealed that some of its senior executives in China may have broken the law.

Benefiting From the Rotation To Cyclicals

Benefiting From the Rotation To Cyclicals

Jim Cramer and Stephanie Link, Co-Portfolio Managers of AAP, discuss how they are trading the current bull market.

New Home Demand Drives Toll

New Home Demand Drives Toll

Luxury homebuilder Toll Brothers reported better-than-expected second quarter earnings on increased demand for new homes.

What's Missing in This Market

You can't get away from the need for good yield in an era of commodity inflation.

Buffett's Long-Term, High-Dividend Plays

Let's look at five holdings that stayed in his portfolio for at least a year.

GE Reports 16% Jump in Profit

GE Reports 16% Jump in Profit

General Electric reports a first quarter profit rising 16%, meeting estimates. Brittany Umar details that and the morning's other top news.

Cramer Talks Abbott & Glaxo

Cramer Talks Abbott & Glaxo

TheStreet's Jim Cramer says Abbott Labs will benefit from growth in emerging markets and Glaxo will benefit from a "huge pipeline of approvals." The Action Alerts Plus portfolio recently bought Glaxo shares and added to their position in Abbott Labs.

The Biotech Revaluation Is On

These four names in particular have made some stunning moves.

Mad Money Uncovered: Merck and the Pharma Laggards

Mad Money Uncovered: Merck and the Pharma Laggards

Jim Cramer looks at why he is highlighting pharma along with growth biotech, with Nicole Urken, Mad Money Research Associate.

Mega-Hedge Fund Manager Seth Klarman's Five Best Stock Picks

Klarman's hedge funds' top small-cap picks generate significant alpha.

The Next Big Thing in Biotech: Dynavax

The Next Big Thing in Biotech: Dynavax

Senior columnist Adam Feuerstein says Dynavax Technologies is the next big thing to watch in biotech.

A Prescription for Election Fever

Now is the time to pop the pharmaceutical pill and buy.

GlaxoSmithKline downgraded at UBS

They Just Don't Get Glaxo!

They Just Don't Get Glaxo!

Marek Fuchs, senior contributing analyst at TheStreet, talks proportion on Glaxo.

Pipeline Full, Dividend Secure, Says Glaxo CFO

Pipeline Full, Dividend Secure, Says Glaxo CFO

Simon Dingemans, CFO of GlaxoSmithKline, discusses the company's bid for Human Genome, Obamacare and the company's growing emerging-market business.

Auxilium On a Roll with Xiaflex, Testim Deal

Auxilium On a Roll with Xiaflex, Testim Deal

Adrian Adams, CEO of Auxilium, discusses the company's breakthrough with Xiaflex, as well as recent news surrounding its drug Testim.

Biotech Breakout

Biotech Breakout

SPDR S&P Biotech ETF is likely to post new highs in the second quarter.

GlaxoSmithKline Takes Human Genome Bid Hostile: Hot Trends

GlaxoSmithKline Takes Human Genome Bid Hostile: Hot Trends

A look at the day's most searched trends on the Web, including GlaxoSmithKline's intentions to take its bid for Human Genome Sciences hostile.

The Next Big Thing in Biotech: M&A

The Next Big Thing in Biotech: M&A

Senior columnist Adam Feuerstein says M&A is the next big thing in biotech.

Three Cheap Speculative Bets

Aviat, Capstone and Axcelis are high-reward/high-risk plays for under $2.50.

EU OKs J&J's $21.3B Synthes Takeover: Hot Trends

EU OKs J&J's $21.3B Synthes Takeover: Hot Trends

A look at the day's most searched topics on the Web, including the European Union's approval of Johnson & Johnson's $21.3 billion takeover of Synthes.

Playing in Biotech -- A Primer

Biotech is changing, so here's how to invest amid the industry's new gold rush.

Safe Stocks for Your Income Portfolio

If you need to live on investment income, bonds and CDs are not enough -- you need dividends.

Ligand Pharma Still Worth a Shot

Ligand Pharma Still Worth a Shot

The damage to a big drug's approval odds is much less than is presently priced into LGND.